Island -
islandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
ceftriaxon fresenius kabi stungulyfs-/innrennslisstofn, lausn 1 g
fresenius kabi ab - ceftriaxonum dínatríum - stungulyfs-/innrennslisstofn, lausn - 1 g
Island -
islandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
natriumklorid fresenius kabi leysir fyrir stungulyf 9 mg/ml
fresenius kabi ab - natrii chloridum - leysir fyrir stungulyf - 9 mg/ml
Island -
islandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
natriumklorid fresenius kabi innrennslislyf, lausn 9 g/1000 ml
fresenius kabi ab - natrii chloridum - innrennslislyf, lausn - 9 g/1000 ml
Island -
islandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
ondansetron fresenius kabi stungulyf, lausn 2 mg/ml
fresenius kabi ab - ondansetronum hýdróklóríð - stungulyf, lausn - 2 mg/ml
Island -
islandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
ceftazidim fresenius kabi stungulyfs-/innrennslisstofn, lausn 2000 mg
fresenius kabi ab - ceftazidimum pentahýdrat - stungulyfs-/innrennslisstofn, lausn - 2000 mg
Island -
islandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
ceftazidim fresenius kabi stungulyfsstofn, lausn 1000 mg
fresenius kabi ab - ceftazidimum pentahýdrat - stungulyfsstofn, lausn - 1000 mg
Island -
islandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
ceftriaxon fresenius kabi innrennslisstofn, lausn 2 g
fresenius kabi ab - ceftriaxonum dínatríum - innrennslisstofn, lausn - 2 g
Island -
islandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
smofkabiven perifer innrennslislyf, fleyti
fresenius kabi ab - glucosum; alaninum inn; argininum inn; glycinum inn; histidinum inn; isoleucinum inn; leucinum inn; methioninum inn; phenylalaninum inn; prolinum inn; serinum inn; taurinum inn; threoninum inn; tryptophanum inn; tyrosinum inn; valinum inn; kalii chloridum; zinci sulfas; soiae oleum raffinatum; triglycerides medium chain; olivae oleum raffinatum; fish oil rich in omega-3 acids; calcii chloridum; lysinum inn; magnesii sulfas; natrii acetas; natrii glycerophosphas - innrennslislyf, fleyti
Euroopa Liit -
islandi -
EMA (European Medicines Agency)
budesonide/formoterol teva pharma b.v.
teva pharma b.v. - budesonide, formoterol - astma - lyf til veikindi öndunarvegi sjúkdómum, - budesonid / formoterol teva pharma b. er ætlað fullorðnum 18 ára og eldri. asthmabudesonide/formóteróli sjá pharma b. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists. in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.
Island -
islandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
myfortic magasýruþolin tafla 180 mg
novartis healthcare a/s - mycophenolatum natríum - magasýruþolin tafla - 180 mg